| Category | Details |
| Definition | Arthritis encompasses over 100 conditions causing joint inflammation, pain, stiffness, and reduced mobility. Osteoarthritis (OA) and rheumatoid arthritis (RA) are the most common types. |
| Global Epidemiology | – Affects ~350 million people globally. |
| -Osteoarthritis impacts approximately 595 million people globally, making it the most common joint disease worldwide. |
| – Rheumatoid arthritis affects approximately 17.6 million people globally, representing about 0.22% of the population as of 2020. |
| Prevalence in Key Regions | – United States: ~58 million adults live with arthritis; RA prevalence ~1.3 million. |
| – European Union: ~100 million cases; OA and RA most common in aging populations. |
| – India: ~70 million people affected, with OA prevalence rising due to aging and obesity trends. |
| – China: Estimated ~100 million cases of arthritis, including OA and RA. |
| – Caribbean: ~6–8 million people affected, with limited access to advanced therapies. |
| Medicinal Cannabis Approvals | – United States (FDA): No specific approvals; off-label use of cannabinoids common for chronic pain. |
| – Canada: Approved CBD products for chronic pain management; off-label use for arthritis prevalent. |
| – European Union (EMA): Limited approvals; cannabinoids studied for pain and inflammation management. |
| – Australia (TGA): Approved cannabinoids for chronic pain, including arthritis, since 2017. |
| – Israel: Medical cannabis authorized for arthritis and chronic joint pain since 2013. |
| Therapeutic Cannabinoids | – CBD (Cannabidiol): Reduces inflammation and pain; modulates immune responses in RA. |
| – THC (Tetrahydrocannabinol): Provides analgesic and anti-inflammatory effects; psychoactive at higher doses. |
| – CBG (Cannabigerol): Emerging evidence for cartilage protection and anti-inflammatory properties. |
| – THCV (Tetrahydrocannabivarin): Promising for reducing inflammation and pain perception. |
| Mechanism of Action | – CBD: Modulates CB2 receptors to reduce inflammation and cytokine production in affected joints. |
| – THC: Activates CB1 receptors, reducing pain perception and promoting muscle relaxation. |
| – CBG: Inhibits inflammatory pathways and oxidative stress in joint tissues. |
| Key Clinical Studies | – Blake et al., 2006: Sativex reduced RA pain and improved sleep quality in a double-blind trial. |
| – Fitzcharles et al., 2020: CBD has shown potential for reducing pain scores in arthritis patients, contributing to improved quality of life; |
| – Russo et al., 2019: Cannabinoids showed potential for reducing chronic inflammation in RA and OA. |
| Dosage Guidelines | – CBD (Oral): Start at 20 mg/day; titrate to 50–150 mg/day for pain relief. |
| – THC (Oral): Starting dose 2.5 mg/day for pain; increase gradually based on tolerance. |
| – CBG (Experimental): Early trials suggest doses of 10–20 mg/day for anti-inflammatory effects. |
| Administration Methods | – Oral Capsules: Preferred for consistent dosing; suitable for long-term pain management. |
| – Sublingual Oils: Rapid absorption for acute flare-ups; dosage precision required. |
| – Topical Applications: Used for localized pain relief in arthritis-affected joints. |
| Adverse Effects | – CBD: Mild side effects like fatigue, appetite changes, and diarrhea; rare liver enzyme elevation. |
| – THC: Psychoactive effects include dizziness, euphoria, and cognitive impairment; potential dependency. |
| – CBG: Limited evidence; fatigue and dry mouth reported in early trials. |
| Research Gaps | – Long-term safety and efficacy studies of cannabinoids in arthritis management are limited. |
| – Interactions with standard arthritis medications need further investigation. |
| Opportunities in the Caribbean | – High Prevalence: ~6–8 million affected individuals with unmet needs for pain management therapies. |
| – Cannabis Clinics: Establishing cannabinoid-focused clinics could meet local needs and attract medical tourists. |
| – Research Hub: Leveraging regional expertise for cannabinoid-based arthritis treatments. |
